Cytosorbents is engaged in the treatment of life-threatening conditions in the intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co. has several products commercialized and in development based on this technology platform. CytoSorb, Co.'s primary product, is approved in the European Union as an extracorporeal cytokine absorber, designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. We show 37 historical shares outstanding datapoints in our coverage of CTSO's shares outstanding history.
Understanding the changing numbers of CTSO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CTSO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CTSO by allowing them to research CTSO shares outstanding history
as well as any other stock in our coverage universe. |
Free CTSO Email Alerts:
Video: Shares Outstanding Importance
